SPHK1 and pancreatic ductal adenocarcinoma: SPHK1 was earlier reported to be upregulated in pancreatic ductal adenocarcinoma demonstrating resistance to gemcitabine [61], its regulation of angiogenesis [62] and miRNA 506/SPHK1 axis as a therapeutic target [63].